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Antisense agents that target growth-essential genes dis-
play surprisingly potent bactericidal properties. In particu-
lar, peptide nucleic acid (PNA) and phosphorodiamidate 
morpholino oligomers linked to cationic carrier peptides 
are effective in time kill assays and as inhibitors of bacte-
rial peritonitis in mice. It is unclear how these relatively 
large antimicrobials overcome stringent bacterial barri-
ers and mediate killing. Here we determined the transit 
kinetics of peptide–PNAs and observed an accumulation 
of cell-associated PNA in Escherichia coli and slow efﬂux. 
An inhibitor of drug efﬂux pumps did not alter peptide–
PNA potency, indicating a lack of active efﬂux from cells. 
Consistent with cell retention, the post-antibiotic effect 
(PAE) of the anti-acyl carrier protein (acpP) peptide–PNA 
was greater than 11 hours. Bacterial cell accumulation 
and a long PAE are properties of signiﬁcant interest for 
antimicrobial development.
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29 May 2007; doi:10.1038/sj.mt.6300209
INTRODUCTION
Antibiotic resistance is an important medical problem that threat-
ens to reverse or diminish the “antibiotic miracle”. Moreover, the 
development of new drugs using conventional strategies is unlikely 
to keep pace with acquired resistance. Only two new classes of 
antimicrobial agents have been introduced into the clinic in the 
past 35 years. Therefore, new types of antimicrobials, particu-
larly to treat persistent and multi-drug resistant infections,1 are 
urgently needed.
To help provide new types of antimicrobial agents and tools 
for microbial genetics, antisense technologies have been devel-
oped for bacterial applications. Antisense agents are attractive 
for research and therapeutic development because they offer 
the possibility of using simple design rules to inhibit any gene. 
 Bacteria themselves use natural antisense mechanisms2 and may 
be uniquely amenable to antisense control. For example, bac-
teria have relatively small genomes and lack organelles, features 
that naturally increase the chance of target binding and hence of 
gene-specific effects. However, bacteria typically exclude foreign 
molecules with stringent cell barriers and efflux pumps. Fortunately, 
new nucleic acid analogues and mimics—such as peptide nucleic 
acid (PNA) and phosphorodiamidate morpholino oligomers—
have been developed.3,4 Although such oligomers are larger than 
conventional antibiotics, their uncharged backbones appear to 
enable delivery across negatively charged bacterial cell barri-
ers, and positively charged amino acids can be added to provide 
cationic regions within the molecule. These delivery advantages 
have also been exploited in diagnostics applications to provide 
improved antisense probes for in situ staining of microbes.5,6
PNA uptake and antisense effects can be improved using short 
(e.g., 10–12-mer) PNAs and attachment to cationic carrier peptides 
that permeabilize bacterial membranes (e.g., KFFKFFKFFK).7,8 
Indeed, a peptide–PNA directed against the messenger RNA 
(mRNA) encoding the essential acyl carrier protein (acpP), which 
is central to fatty acid biosynthesis, shows bactericidal properties 
in Escherichia coli at nanomolar to low micromolar concentra-
tions.7,9 Certain peptide–PNA and peptide–phosphorodiamidate 
morpholino oligomers targeted against growth-essential genes are 
more bactericidal in vitro and in vivo relative to molar or mass 
equivalent doses of ampicillin and rifampicin, and they act with 
sequence and gene selectivity.7,10–13 Also, a variety of target genes 
and possibly a range of species can be targeted.14–18 One possible 
explanation for this potent killing activity is that antisense mol-
ecules accumulate in bacteria, as reported for certain antibiotics, 
including rifampicin.19
Here we studied the antibacterial effects of antisense peptide–
PNAs to understand how these relatively large molecules are able 
to mediate potent cell killing. Cell morphology, cell transit kinet-
ics, and post-antibiotic effects (PAEs) were assessed using two 
antisense peptide–PNAs that target the non-essential lacZ and 
essential acpP genes at the mRNA level. Conventional antibiotics 
were included for comparison. The results indicate an accumula-
tion of cell-associated PNA and slow efflux. Consistent with the 
cellular transit data, an anti-acpP peptide–PNA showed a strong 
PAE (>11 hours). Thus, although the delivery of antisense agents 
into bacteria is a significant challenge, once delivered the mole-
cule is retained, and this appears to contribute to the bactericidal 
Correspondence: Liam Good, Department of Cell and Molecular Biology (CMB), Karolinska Institutet, Berzelius väg 35, 171 77 Stockholm, Sweden. 
E-mail: liam.good@ki.se
1538 www.moleculartherapy.org  vol. 15 no. 8 aug. 2007  
© The American Society of Gene Therapy
PNA Accumulates in Bacteria and Has a Long PAE
activity. Such accumulation and retention properties are inter-
esting with respect to the potential of antisense agents as drugs 
to treat infections, particularly infections involving persistent or 
drug resistant bacteria.
RESULTS
Anti-acpP peptide–PNA has comparatively potent 
bactericidal activity
Antisense antibacterials show potent bactericidal effects relative 
to ampicillin in in vivo infection models and also in vitro.9,11,13 
Here we aimed to extend this comparison to additional conven-
tional antibiotics and examine the mechanism of cell killing. 
First, we determined the minimal inhibitory concentrations 
(MICs) for the anti-acpP peptide–PNA, a control sequence 
scrambled version of the anti-acpP peptide–PNA and four 
conventional antibiotics in parallel against E. coli (Table 1 and 
 Figure 1). Notably, the MIC for this peptide–PNA was 0.8 μmol/l, 
making it more potent on a molar basis than ampicillin, chlor-
amphenicol, trimethoprim, and streptomycin (Table 1). Next, 
we determined the rate of cell killing by equimolar doses of 
 peptide–PNAs and the conventional antibiotics. The results 
indicate that PNA can rapidly kill E. coli, consistent with pre-
vious reports,7,9 although the rate of killing was slower than 
observed for streptomycin (Figure 1b).
The sequence and gene selectivity of the anti-acpP peptide–
PNA has been examined and reported.7,9 To ensure that selec-
tivity was maintained in this study, we included the sequence 
scrambled version of the peptide–PNA. Again, the control mol-
ecule was not inhibitory in the cell kill assay. Also, we deter-
mined the effect of the targeted and control peptide–PNAs on 
acpP mRNA abundance in growing cells treated with sub-lethal 
concentrations using real-time reverse transcriptase-polymerase 
chain reaction. As expected, the targeted anti-acpP peptide–PNA 
reduced acpP mRNA abundance and the scrambled version was 
not inhibitory (Figure 1c). These results are consistent with 
mRNA reduction in the presence of antisense PNAs,17 and the 
data support a target selective antisense mechanism.
Peptide–PNA treated bacteria remain intact
Bactericidal effects of antimicrobials may be associated with 
cell lysis or membrane damage. To test whether peptide–PNA 
treatment leads to cell lysis, anti-acpP peptide–PNA-treated cells 
were incubated with the nucleic acid ligands SYTOX Green and 
4a,6-diamidino-2-phenylindole (DAPI) and then observed using 
fluorescence microscopy. Both probes stain DNA and RNA and 
display enhanced fluorescence upon binding. However, the two 
probes differ in cell entry properties: DAPI freely enters both 
live and dead cells, whereas SYTOX Green is normally excluded 
from bacteria; positive green staining is taken as an indication 
of cell death.20 PNA-treated cells were compared to untreated 
and heat-killed bacteria. All cells were stained with DAPI, and 
both the peptide–PNA- and heat-treated cells were stained with 
SYTOX Green, indicating that the peptide–PNA-treated cells 
were non-viable (Figure 1d). The results show that peptide–
PNA-killed cells did not lyse but were elongated (Figure 1d). 
Finally, total nucleic acids were isolated from the untreated and 
treated cells and peptide–PNA treatment did not appear to alter 
nucleic acid content (data not shown).
PNAs accumulate in bacteria
Given that the anti-acpP peptide–PNA is bactericidal but does 
not lyse cells, we considered the possibility that PNAs may accu-
mulate in bacteria or show a long retention period following 
exposure. To address this question, we used two experimental 
techniques.
Table 1 MIC and the duration of PAE of antibacterial agents against 
Escherichia coli K12
Antibacterial MIC (μmol/l) PAE duration (h) ± std
Ampicillin 12.5 1.05 ± 0.28
Chloramphenicol 8 2.23 ± 0.36
Streptomycin 1.25 7.32 ± 0.91
Trimethoprim 2 0.89 ± 0.28
Anti acpP peptide–PNA 0.8 11.70 ± 2.6
Anti acpP peptide–PNA scrambled 8 not determined
Abbreviations: acpP, acyl carrier protein; MIC, minimal inhibitory concentration; 
PAE, post-antibiotic effect; PNA, peptide nucleic acid.
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Figure 1 Bactericidal effects of an anti-acyl carrier protein (anti-
acpP) peptide–PNA and conventional antibiotics against Escherichia 
coli. (a) The structure of acpP messenger RNA (mRNA) and anti-acpP 
peptide–PNA. (b) Cultures of E. coli K12 were untreated (g) or treated 
with anti-acpP peptide–PNA (□), anti-acpP peptide–PNA scrambled con-
trol (◊), streptomycin (), chloramphenicol (+), ampicillin ($), and trim-
ethoprim (▼) at 2 μmol/l. Colony forming units (CFUs) were scored by 
culture dilution and plating. (c) Effect of targeted anti-acpP peptide–PNA 
(solid bars) and anti-acpP peptide–PNA scrambled control (hatched 
bars) treatment on acpP mRNA abundance (d) Effect of anti-acpP pep-
tide–PNA treatment on cell morphology, nucleic acid content, and cell 
viability. Control, heat-treated, and anti-acpP peptide–PNA-treated cul-
tures of E. coli K12 were stained with SYTOX Green and 4a,6-diamidino-
2-phenylindole (DAPI) and then observed by ﬂuorescence microscopy 
(s1000). PNA, peptide nucleic acid.
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First, to avoid complications associated with cell death caused 
by the bactericidal peptide–PNA, a non-toxic anti-lacZ peptide–
PNA was used in the transit experiments. The anti-lacZ peptide–
PNA was labeled with the universal labeling system (ULS)-Cy5 
fluorophore, and we observed the level of cell-associated Cy5 
fluorescence in cells that were counter stained with the nucleic 
acid stain DAPI or the membrane stain NanoOrange. When Cy5 
labeled peptide–PNAs were used together with DAPI, the level of 
cell-associated Cy5 fluorescence was much higher than in the sur-
rounding media, indicating that labeled peptide–PNA accumulated 
with cells (Figure 2a). In this experiment, it is important to note 
that the cells were not rinsed before microscopy, which allowed us 
to view cellular accumulation. Also, the quantum yield for cyanine 
dyes does not alter substantially in different cellular environments, 
whereas DAPI and NanoOrange fluorescence quantum yield 
increases greatly when these dyes bind to nucleic acids and pro-
teins, respectively. When the ULS-Cy5 labeled peptide–PNA was 
used together with NanoOrange, the Cy5 fluorescence appeared 
to accumulate in cells. Red fluorescence was visible inside the 
halo of NanoOrange fluorescence, indicating that a proportion 
of the labeled PNAs were localized in the bacterial cytoplasm 
(Figure 2b). Therefore, although qualitative, the fluorescence data 
indicate an accumulation of PNA in cells. Finally, to monitor the 
efflux of fluorophore labeled PNAs, cells were treated as described 
above, rinsed once with fresh media, and then viewed after 2 and 
4 hours. Cell-associated fluorescence was retained but was reduced 
at 4 hours, indicating a slow rate of efflux (Figure 2c).
Second, to assess peptide–PNA uptake and efflux rates using 
a quantitative method, we established a gel shift assay for cell-
 associated anti-lacZ peptide–PNA as in a method previously 
used to determine PNA concentration in brain tissue.21 An 
advantage with this assay is that it can be applied to unlabeled 
PNAs. A labeled complementary DNA oligonucleotide is used, 
and formation of a DNA::PNA duplex is observed as a retarded 
band following fractionation using agarose gel electrophoresis. 
To generate a standard curve, E. coli cell lysates were spiked with 
anti-lacZ peptide–PNA, allowed to hybridize with fluorescein 
isothiocyanate (FITC)-labeled complementary DNA oligonu-
cleotides for 3 hours, and then subjected to gel electrophoresis 
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Figure 2 Accumulation of ﬂuorophore labeled peptide nucleic acid 
(PNA). Escherichia coli was treated with ﬂuorophore labeled peptide–PNA 
and observed by ﬂuorescence microscopy (s1000). (a) E. coli cells were 
treated with ULS-Cy5 labeled anti-lacZ peptide–PNA and counter stained 
with 4a,6-diamidino-2-phenylindole (DAPI). (b) E. coli cells were treated 
with ULS-Cy5 labeled anti-lacZ peptide-PNA. Cell membranes were counter 
stained with NanoOrange. (c) E. coli cells were treated with ULS-Cy5 labeled 
anti-lacZ peptide–PNAs and viewed following a rinse cycle at 2 and 4 hours.
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Figure 3 Quantiﬁcation of cell-associated peptide nucleic acid (PNA) 
in cell lysates. Standard curves for PNA in cell lysates. (a) The structure 
of anti-lacZ peptide–PNA along with the complementary FITC-DNA 
oligomer. (b) Gel shift analysis of hybridized PNA in a 3% agarose gel. 
(c) PNA::DNA band intensity was plotted against PNA concentration to 
provide a standard curve. FITC, ﬂuorescein isothiocyanate.
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Figure 4 Uptake and efﬂux kinetics. The gel shift shows retarded bands, 
which indicate cell-associated anti-lacZ peptide–PNA. A free FITC-DNA 
oligomer was used as a control (c; lane 1). Cell-associated PNA concen-
trations were determined using a standard curve and then plotted. FITC, 
ﬂuorescein isothiocyanate; PNA, peptide nucleic acid.
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(Figure 3). The fluorescent images were collected (Figure 3b) 
and quantified using image analysis software and then plot-
ted (Figure 3c). The standard curve was used to quantify cell-
 associated PNA in the subsequent analyses.
To determine uptake kinetics, freshly grown E. coli cultures 
were treated with 2 μmol/l anti-lacZ peptide–PNA; samples were 
harvested at intervals up to 5 hours, rinsed thoroughly, and sub-
jected to PNA quantification (Figure 4). The data indicate that the 
cell-associated PNA concentration exceeded the initial medium 
concentration (2 μmol/l) within 30 minutes. The amount of cell-
associated PNA increased further up to 5 hours.
To determine efflux kinetics, E. coli were grown in the pres-
ence of 2 μmol/l anti-lacZ peptide–PNA for 20 hours and then 
rinsed with fresh media; samples were harvested at time intervals 
up to 5 hours and analyzed as described above. The gel shift pro-
file and the PNA efflux kinetics are illustrated in Figure 4. The 
data indicate that PNA accumulated to 7.3 μmol/l in bacteria after 
20 hours and was retained at comparatively high concentrations 
(>3.5 μmol/l) for up to 5 hours.
The efﬂux pump inhibitor Phe-Arg-β-naphthylamide 
does not affect peptide–PNA potency
Efflux pumps in bacteria reduce the potency of many antimi-
crobials and provide a common mechanism of multi-drug resis-
tance. The slow efflux kinetics for PNA described here, together 
with previous results using mutant bacteria,22 suggest that PNAs 
are unlikely to be substrates for efflux pumps. To examine this 
issue further, we used the efflux pump inhibitor Phe-Arg-β-
 naphthylamide (PAβN), which inhibits a broad spectrum of 
efflux pumps in a variety of gram-negative bacteria and also dra-
matically sensitizes E. coli to several antibiotics.23 E. coli were 
treated with increasing doses of PAβN and also with increasing 
doses of rifampicin or anti-acpP peptide–PNA. The effects on 
growth are illustrated in Figure 5. Whereas the inhibitory con-
centrations for rifampicin were dramatically reduced by PAβN, 
peptide–PNA activity was unchanged. Therefore, the results 
using this pump inhibitor support the notion that antisense anti-
bacterials are unlikely substrates for efflux pumps.
Anti-acpP peptide–PNAs display a long PAE
To determine whether the accumulation and retention of PNA 
in E. coli results in a long PAE, we subjected peptide–PNA and 
four conventional antibiotics to a standard PAE assay.24 E. coli 
growth was severely delayed in the presence of streptomycin and 
anti-acpP peptide–PNA relative to the other antibiotics tested 
(Figure 6; Table 1).
DISCUSSION
The results of this study show that the anti-acpP peptide–PNA 
is more potent than several conventional antimicrobials in stan-
dard MIC and cell killing assays. Also, peptide–PNA treatment 
did not lyse cells or alter gross cellular integrity or content. The 
bactericidal activity of conventional antimicrobials is often asso-
ciated with cell lysis; therefore, it is important to understand the 
mechanisms that underlie the activity of antisense antibacterials. 
If it is true that antisense peptide–PNAs kill cells in the absence 
of lysis, then cell killing is likely to involve a long period of PNA 
retention. The anti-acpP peptide–PNA targets an essential fatty 
acid biosynthesis gene, and cells that retain PNA may be unable 
to divide and may die from a lack of fatty acid biosynthesis even 
after the growth environment has been depleted of PNA. PNA 
retention could involve target affinity, carrier peptide decay, or 
an inability to exit across asymmetric cell membrane structures 
and charge gradients.
The results from fluorescence microscopy of labeled PNAs 
and quantification of cell-associated unlabeled PNAs indicate 
rapid uptake, slow efflux, and an accumulation in cells. The 
results for cell retention are striking: the literature indicates that 
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Figure 5 Growth of Escherichia coli K12 treated with rifampicin 
or anti-acpP peptide–PNA in combination with the efﬂux pump 
 inhibitor Phe-Arg-β-naphthylamide (PAβN). Growth was measured by 
monitoring culture turbidity at optical density (OD550). The panel at left 
shows cultures treated with 0 (○), 2 (□), 4a (), 6 (s), 8 (+), and 10 μmol/l 
(∆) rifampicin in the absence or presence of PAβN (0, 5, 10 μmol/l). The 
panel at right shows growth of cultures treated with 0 (○), 0.15 (□), 0.3 
(), 0.45 (s), 0.6 (+), and 0.75 μmol/l (∆) anti-acpP peptide–PNA in the 
absence or presence of PAβN (0, 5, and 10 μmol/l). acpP, acyl carrier 
protein; PNA, peptide nucleic acid.
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Figure 6 Post-antibiotic effect (PAE). Cultures of bacteria were untrea-
ted (g) or treated for 1 hour with anti-acpP peptide–PNA (□), streptomy-
cin (), chloramphenicol (+), ampicillin (∆), and trimethoprim (▼) at s5 
their MIC. The PAEs are shown as representative curves from ﬁve replicate 
experiments (see Table 1). MIC, minimal inhibitory concentration.
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conventional antibiotics efflux from E. coli within minutes,25 
whereas PNAs are retained for several hours (Figures 2 and 4). 
Also, PNAs do not appear to be removed by efflux pumps. A long 
period of cellular retention suggested that these molecules would 
display a long PAE. Indeed, we observed a PAE of >11 hours 
(Table 1), which to our knowledge is longer than other examples 
reported in the literature. Therefore, PNAs accumulate in bac-
teria, are retained without active efflux, and show a long PAE. 
These properties appear to explain the potent bactericidal effects 
observed in vitro and in vivo.9,11,13 
A criticism against efforts to develop antisense oligomers as 
drugs, and as antimicrobials in particular, is that such molecules 
are inherently too large to achieve efficient cell uptake and in vivo 
distribution. However, as we have described here, peptide–PNA 
and peptide–phosphorodiamidate morpholino oligomer based 
antimicrobials perform well in cell kill assays in vitro and in vivo. 
Also, there is renewed interest from clinicians in the efficacy of 
larger molecular weight antimicrobials.26 Therefore, mechanisms 
that explain the activity of relatively large molecular weight anti-
microbials should be considered because they may broaden the 
scope for chemists to develop new classes of antimicrobials.
The present data indicate that the cellular transit kinetics of 
PNA leads to an accumulation in cells. The delivery of antisense 
agents into bacteria remains a significant challenge; once deliv-
ered, however, the molecule is retained, and this may contribute 
to potent antimicrobial activity and a long PAE. The antisense 
mechanism and accumulation propensities may prove particularly 
appropriate in new strategies for treating persistent, dormant, or 
drug resistant infections.
MATERIALS AND METHODS
Bacteria, growth medium, and antimicrobials. E. coli K12 was obtained 
from the Coli Genetic Stock Center (http://cgsc.biology.yale.edu). Mueller–
Hinton (MH) broth, antimicrobial drugs, and PAβN were purchased 
from Sigma-Aldrich (St. Louis, MO). Cells were grown in 96-well low 
attachment plates (COSTAR 3474, Corning, Lowell, MA). The anti-acpP 
((KFF)3K-eg1-ctcatactct), the anti-acpP scrambled control ((KFF)3K-eg1-
tcactatctc), and the anti-lacZ ((KFF)3K-eg1-catagctgtttc) peptide–PNAs 
complementary to the start codon regions of the acpP and lacZ genes, 
respectively, have been described.7 The peptide–PNAs were obtained from 
Panagene (Daejeon, Korea).
MIC and colony forming unit determinations. E. coli K12 cultures were 
grown overnight and diluted to 5 s 105 cells/ml in MH broth, and 80 μl ali-
quots were added to wells of a low attachment 96-well plate. Antimicrobial 
aliquots (20 μl) of different concentrations were added to give a final volume 
of 100 μl. Plates were incubated for 20 hours at 37 °C in a VersaMax spec-
trophotometer with shaking, and optical density (OD550) measurements 
were taken every 5 minutes. MICs were scored as the lowest concentration 
of an antimicrobial needed to prevent measurable growth after 20 hours.
To measure colony forming units, antimicrobials were added to bacte-
rial cultures to a final concentration of 2 μmol/l, as described previously. 
Cultures were harvested at 0, 1, 2, 4, and 6 hours. The content of each well 
was added to 0.9 ml of MH broth and centrifuged at 9300g for 5 minutes. 
Supernatants were removed and the cell pellets were suspended in fresh 
pre-warmed MH broth (100 μl). Tenfold serial dilutions were prepared, 
and 20 μl aliquots were plated on Luria–Bertani agar plates and incubated 
overnight at 37 °C.
Relative quantitative polymerase chain reaction of acpP mRNA in 
 peptide–PNA-treated E. coli. E. coli K12 cultures were grown overnight 
and diluted to 5 s 105 cells/ml in MH broth, and 180 μl aliquots were added 
to the wells of a low attachment 96-well plate. Anti-acpP or anti-acpP 
scrambled control peptide–PNAs (20 μl) of varying concentrations (0, 80, 
100, 120 nmol/l) were added to give a final volume of 200 μl. These con-
centrations were chosen to provide sufficient growth inhibition and RNA 
yield. The plate was incubated at 37 °C in a VersaMax spectrophotometer 
with shaking, and OD550 measurements were taken every 5 minutes until 
an increase in OD550 of ^0.1 in the untreated cultures was reached. The 
content of 4–32 wells were pooled for total RNA extraction and treat-
ment with DNase I using the RiboPure Bacteria kit (Ambion (Europe) 
LTD, Cambridgeshire, UK), according to the manufacturer’s protocol. 
RNA (250 ng) was converted to complementary DNA in a 25 μl reaction 
consisting of 1s reverse transcription reaction buffer, 5.5 mmol/l Mg2+, 
500 μmol/l of each dNTP, 2.5 μmol/l random hexamers, 10 U RNase 
inhibitor, and 31.5 U Multiscribe reverse transcriptase (Applied Biosys-
tems, Foster City, CA). Relative quantitative polymerase chain reaction 
was then carried out with 5 ng of complementary DNA in a 25 μl reac-
tion consisting of 1s SYBR Green 1 reaction buffer (Eurogentec SA, 
 Seraing, Belgium), 100 nmol/l of acpP-F (5a CAGGAAGAAGTTACCAA 
CAATGCTT 3a) and acpP-R (5a-CCAGCTCAACGGTGTCAAGA-3a) pri-
mers or 100 nmol/l of rpoA-F (5a-AAGCTGGTCATCGAAATGGAA-3a) 
and 150 nmol/l of rpoA-R (5a-GCCGCACGACGAATCG-3a) primers. 
 Amplification efficiencies of the target gene, acpP, and the reference gene, 
rpoA, were validated (109%), and data analyses were carried out by the 
2–ΔΔCT method.27 The averages of three sample replicates were used to 
calculate mRNA abundance of peptide–PNA-treated samples relative to 
untreated samples. The experimental procedure was repeated three times, 
and mean values with error bars representing standard deviation were 
plotted as a histogram.
Fluorescence microscopy. Freshly grown cells were observed without 
fixation or post stain rinsing with a Leica DMRA2 microscope (Leica 
Mikroskopie and Systeme GmbH, Wetzlar, Germany) at s1000 and the 
images were processed using Openlab software version 3.1.4 (Improvi-
sion, Coventry, England). To examine cell viability, cells were stained with 
1 μmol/l SYTOX Green membrane integrity indicator stain (Invitrogen 
Ltd, Paisley, UK) and DAPI (2 μg/ml). To observe peptide–PNA uptake, 
peptide–PNAs were labeled with Cy5 using the Kreatech ULS (Kreatech 
Biotechnology, Amsterdam, The Netherlands). In a 500 μl microcentrifuge 
tube, 2 μg anti-lacZ peptide–PNA was mixed with 2 μl reaction buffer, 2 μl 
Cy5-ULS reagent, and water to 20 μl total and then incubated at 85 °C for 
4 hours. The labeled peptide–PNA was purified using a Pierce PepClean 
C18 spin column (Pierce #89870; Pierce Biotechnology, Rockford, IL). 
The column was pre-rinsed with 150 μl 50% acetonitrile and equilibrated 
twice with 150 μl solution of 5% acetonitrile containing 0.5% trifluorac-
etate. The reaction mixture was diluted in 150 μl 5% acetonitrile contain-
ing 0.5% trifluoracetate and then loaded onto the column and centrifuged 
at 1000g. The column was rinsed with a gradient of 10, 20, 25, and 30% 
acetonitrile (150 μl, 0.5% trifluoracetate). The labeled product was eluted 
with 70% acetonitrile (0.5% trifluoracetate), dried under vacuum, and 
then dissolved in 20 μl water. The labeled peptide–PNA was added to 
cells at 2 μmol/l, and the cells were counter stained with a 1/20 dilution of 
NanoOrange dye (Invitrogen Ltd, Paisley, UK) and DAPI.
Quantiﬁcation of cell-associated PNA. Overnight cultures were 
diluted to 5 s 105 colony forming units/ml in MH broth, and 80 μl ali-
quots were added to the wells of a low attachment 96-well plate. Water 
or peptide–PNA solution (2 μmol/l final) was added to 100 μl and the 
plate was incubated for 24 hours as described above. The contents of two 
wells were pooled and added to 1.3 ml pre-warmed MH broth in coated 
1.5 ml tubes (Maxymum Recovery; Axygen Scientific, Union City, CA). 
Bacteria were harvested by centrifugation for 3 minutes at 2300g. After 
removing the supernatant, the tubes were briefly centrifuged to remove 
residual liquid. Cell pellets were resuspended in 1.5 ml pre-warmed MH 
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broth. The rinse and centrifugation steps were repeated. Cell pellets were 
resuspended in 5 μl water and transferred to a fresh tube. To lyse cells, 
15 μl yeast protein extraction reagent (Pierce Biotechnology) was added, 
cells were shaken overnight at room temperature and then sonicated 
for 10 minutes using 30-second pulses at high intensity in a Diagenode 
Bioruptor (Diagenode SA, Liege, Belgium). Cell debris was precipitated 
by 5 minutes of centrifugation at 9300g, and supernatants were trans-
ferred to fresh tubes. An FITC-labeled DNA oligonucleotide (5a-aaattt 
gaaacagctatg-3a) (Thermo Fisher Scientific, Waltham, MA) was added to 
10 μl of cell lysate to give 0.2 μmol/l in 11 μl final volume. The mixture 
was incubated at 37 °C for 3 hours and fractionated by electrophoresis 
in a 3% agarose gel. The gel was scanned using a Typhoon 9400 Scanner 
(Amersham Biosciences, Piscataway, NJ) using green excitation (532 nm) 
and emission (526 nm, short pass) filters and the photomultiplier tube 
set at 550 V. Images were processed using ImageQuant software version 
5 (Amersham Biosciences). To determine the concentration of cell-asso-
ciated PNA, the concentrations of PNA in cell lysates were related to 
cell volumes. To estimate cell volumes, cell mass was first determined 
by drying equivalent aliquots overnight in a Speed-Vac followed by dry 
weight measurements using an analytical balance. The cell dry weight 
was taken as 3.0 s 10–13 g/cell and was converted to volume using the 
value 1 s 10–15 L/cell.
PAE. PAE values were determined essentially as described.24 Cultures of 
E. coli K12 were grown to early exponential phase (109 cells/ml) in MH 
broth in a VersaMax spectrophotometer with shaking. OD550 measure-
ments were taken at 5-minute intervals. The bacterial cultures were diluted 
to 107 cells/ml in MH broth, and 80 μl aliquots were added to the wells of a 
low attachment 96-well plate. Test antimicrobial aliquots (20 μl) were added 
to give 5s MIC (100 μl final volumes). The 96-well plate was incubated for 
60 minutes at 37 °C as described above. Bacteria were harvested by cen-
trifugation at 2300g for 5 minutes, and the cell pellets were suspended in 
fresh pre-warmed MH broth (100 μl). The rinse cycle was repeated twice, 
and the plates were incubated for 24 hours at 37 °C as described previously. 
PAE duration was calculated by subtracting the time taken for the control 
culture to reach 50% of the ODmax from the time taken for antimicrobial-
treated cultures to reach the same OD.
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